Background Hepatic encephalopathy is a common complication of cirrhosis and has high
associated morbidity and mortality. The condition is classified as overt if it is clinically …

This manuscript represents an appraisal of the evidence in support of l-ornithine-l-aspartate
(LOLA) for the management and treatment of hepatic encephalopathy (HE) in cirrhosis. Meta …

BACKGROUND/AIMS: Studies in acute liver failure show correlation between evidence of a
systemic inflammatory response syndrome (SIRS) and progression of hepatic …

Metabolic processes utilize a variety of differing and contrasting biochemical routes to
enable synthesis of degradation and activation or deactivation of substances; in addition …

Background: Minimal hepatic encephalopathy (MHE) is common in cirrhosis but its
pathophysiologic basis remains undefined. We evaluated whether the presence of MHE was …

BACKGROUND & AIMS: In acute liver failure (ALF), high blood ammonia levels have been
documented that correlate with mortality and complications. L-ornithine L-aspartate (LOLA) …

In the post-absorptive state, ammonia is produced in equal amounts in the small and large
bowel. Small intestinal synthesis of ammonia is related to amino acid breakdown, whereas …

Background/objectives l-Ornithine l-Aspartate (LOLA) is a mixture of two endogenous amino
acids with the capacity to fix ammonia in the form of urea and/or glutamine. Its' efficacy for …

Background Interventional treatment for overt hepatic encephalopathy (OHE), includes non‐
absorbable disaccharides, neomycin, rifaximin, L‐ornithine‐L‐aspartate and branched …

Hepatic encephalopathy (HE) is a serious neuropsychiatric and neurocognitive complication
of acute and chronic liver disease. Symptoms are often overt (confusion, disorientation …